Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

Aurelien Marabelle; David M. O’Malley; Andrew E. Hendifar; Paolo A. Ascierto; Daniel Motola-Kuba; Nicolas Penel; Philippe A. Cassier; Giovanni Bariani; Ana De Jesus-Acosta; Toshihiko Doi; Federico Longo; Wilson H. Miller; Do Youn Oh; Maya Gottfried; Lili Yao; Fan Jin; Alexander Gozman; Michele Maio

doi:10.1038/s43018-024-00894-y

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

Aurelien Marabelle, David M. O’Malley, Andrew E. Hendifar, Paolo A. Ascierto, Daniel Motola-Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni Bariani, Ana De Jesus-Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller, Do Youn Oh, Maya Gottfried, Lili Yao, Fan Jin, Alexander Gozman, Michele Maio

CIC 1428 - Clinical investigation center BIOTHERIS [Dir. L TSELIKAS]

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

The phase 2 trial KEYNOTE-158 (NCT02628067) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up, the primary endpoint of overall response rate was 33.8%. Secondary endpoints of duration of response, overall survival and progression-free survival were 63.2, 19.8 and 4.0 months, respectively. Grade ≥3 treatment-related adverse events occurred in 50 (13%) participants. These results further support pembrolizumab use in MSI-H/dMMR tumors.

langue originale	Anglais
Pages (de - à)	253-258
Nombre de pages	6
journal	Nature Cancer
Volume	6
Numéro de publication	2
Les DOIs	https://doi.org/10.1038/s43018-024-00894-y
état	Publié - 1 févr. 2025

Accès au document

10.1038/s43018-024-00894-y

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Marabelle, A., O’Malley, D. M., Hendifar, A. E., Ascierto, P. A., Motola-Kuba, D., Penel, N., Cassier, P. A., Bariani, G., De Jesus-Acosta, A., Doi, T., Longo, F., Miller, W. H., Oh, D. Y., Gottfried, M., Yao, L., Jin, F., Gozman, A., & Maio, M. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer, 6(2), 253-258. https://doi.org/10.1038/s43018-024-00894-y

@article{1f06824d941d4247a66e00cbbbfe9ff7,

title = "Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial",

abstract = "The phase 2 trial KEYNOTE-158 (NCT02628067) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up, the primary endpoint of overall response rate was 33.8%. Secondary endpoints of duration of response, overall survival and progression-free survival were 63.2, 19.8 and 4.0 months, respectively. Grade ≥3 treatment-related adverse events occurred in 50 (13%) participants. These results further support pembrolizumab use in MSI-H/dMMR tumors.",

author = "Aurelien Marabelle and O{\textquoteright}Malley, {David M.} and Hendifar, {Andrew E.} and Ascierto, {Paolo A.} and Daniel Motola-Kuba and Nicolas Penel and Cassier, {Philippe A.} and Giovanni Bariani and {De Jesus-Acosta}, Ana and Toshihiko Doi and Federico Longo and Miller, {Wilson H.} and Oh, {Do Youn} and Maya Gottfried and Lili Yao and Fan Jin and Alexander Gozman and Michele Maio",

note = "Publisher Copyright: {\textcopyright} Merck & Co., Inc., Rahway, NJ, USA and its affiliates, and The Authors under exclusive licence to Springer Nature America, Inc. 2025.",

year = "2025",

month = feb,

day = "1",

doi = "10.1038/s43018-024-00894-y",

language = "English",

volume = "6",

pages = "253--258",

journal = "Nature Cancer",

issn = "2662-1347",

number = "2",

}

Marabelle, A, O’Malley, DM, Hendifar, AE, Ascierto, PA, Motola-Kuba, D, Penel, N, Cassier, PA, Bariani, G, De Jesus-Acosta, A, Doi, T, Longo, F, Miller, WH, Oh, DY, Gottfried, M, Yao, L, Jin, F, Gozman, A & Maio, M 2025, 'Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial', Nature Cancer, VOL. 6, Numéro 2, p. 253-258. https://doi.org/10.1038/s43018-024-00894-y

TY - JOUR

T1 - Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors

T2 - updated results of the KEYNOTE-158 trial

AU - Marabelle, Aurelien

AU - O’Malley, David M.

AU - Hendifar, Andrew E.

AU - Ascierto, Paolo A.

AU - Motola-Kuba, Daniel

AU - Penel, Nicolas

AU - Cassier, Philippe A.

AU - Bariani, Giovanni

AU - De Jesus-Acosta, Ana

AU - Doi, Toshihiko

AU - Longo, Federico

AU - Miller, Wilson H.

AU - Oh, Do Youn

AU - Gottfried, Maya

AU - Yao, Lili

AU - Jin, Fan

AU - Gozman, Alexander

AU - Maio, Michele

N1 - Publisher Copyright: © Merck & Co., Inc., Rahway, NJ, USA and its affiliates, and The Authors under exclusive licence to Springer Nature America, Inc. 2025.

PY - 2025/2/1

Y1 - 2025/2/1

N2 - The phase 2 trial KEYNOTE-158 (NCT02628067) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up, the primary endpoint of overall response rate was 33.8%. Secondary endpoints of duration of response, overall survival and progression-free survival were 63.2, 19.8 and 4.0 months, respectively. Grade ≥3 treatment-related adverse events occurred in 50 (13%) participants. These results further support pembrolizumab use in MSI-H/dMMR tumors.

AB - The phase 2 trial KEYNOTE-158 (NCT02628067) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up, the primary endpoint of overall response rate was 33.8%. Secondary endpoints of duration of response, overall survival and progression-free survival were 63.2, 19.8 and 4.0 months, respectively. Grade ≥3 treatment-related adverse events occurred in 50 (13%) participants. These results further support pembrolizumab use in MSI-H/dMMR tumors.

UR - http://www.scopus.com/inward/record.url?scp=85218273329&partnerID=8YFLogxK

U2 - 10.1038/s43018-024-00894-y

DO - 10.1038/s43018-024-00894-y

M3 - Article

AN - SCOPUS:85218273329

SN - 2662-1347

VL - 6

SP - 253

EP - 258

JO - Nature Cancer

JF - Nature Cancer

IS - 2

ER -